BR112018011324A2 - ?composições contendo decitabina, 5azacitidina e tetra-hidrouridina e usos das mesmas? - Google Patents

?composições contendo decitabina, 5azacitidina e tetra-hidrouridina e usos das mesmas?

Info

Publication number
BR112018011324A2
BR112018011324A2 BR112018011324A BR112018011324A BR112018011324A2 BR 112018011324 A2 BR112018011324 A2 BR 112018011324A2 BR 112018011324 A BR112018011324 A BR 112018011324A BR 112018011324 A BR112018011324 A BR 112018011324A BR 112018011324 A2 BR112018011324 A2 BR 112018011324A2
Authority
BR
Brazil
Prior art keywords
tetrahydrouridine
compositions containing
decitabine
containing decitabine
compositions
Prior art date
Application number
BR112018011324A
Other languages
English (en)
Inventor
Lau Henry
Desimone Joseph
Vadivelu Santhosh
Saunthararajah Yogen
Original Assignee
Epidestiny Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidestiny Inc filed Critical Epidestiny Inc
Publication of BR112018011324A2 publication Critical patent/BR112018011324A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composições compreendendo decitabina e tetra-hidrouridina ou 5-azacitidina e tetra-hidrouridina para o tratamento de câncer são divulgadas. as composições na forma de uma pílula são administradas a um sujeito humano sequencialmente ou alternadamente guiadas pela medição de biomarcadores preditivos.
BR112018011324A 2015-12-03 2016-12-05 ?composições contendo decitabina, 5azacitidina e tetra-hidrouridina e usos das mesmas? BR112018011324A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262839P 2015-12-03 2015-12-03
US201662429292P 2016-12-02 2016-12-02
PCT/US2016/064935 WO2017096357A1 (en) 2015-12-03 2016-12-05 Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof

Publications (1)

Publication Number Publication Date
BR112018011324A2 true BR112018011324A2 (pt) 2018-12-04

Family

ID=58798100

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011324A BR112018011324A2 (pt) 2015-12-03 2016-12-05 ?composições contendo decitabina, 5azacitidina e tetra-hidrouridina e usos das mesmas?

Country Status (9)

Country Link
US (3) US11376270B2 (pt)
EP (2) EP3383406B1 (pt)
JP (2) JP7194021B2 (pt)
CN (1) CN109789155A (pt)
BR (1) BR112018011324A2 (pt)
CA (1) CA3007357C (pt)
DK (1) DK3383406T3 (pt)
MX (2) MX2021007569A (pt)
WO (1) WO2017096357A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220226355A1 (en) * 2019-05-24 2022-07-21 The Cleveland Clinic Foundation Timed alternate administration of decitabine and 5-azacytidine for cancer treatment
US20210077492A1 (en) * 2019-09-17 2021-03-18 The Trustees Of Indiana University Methods and compositions of treating pancreatic cancer
WO2021211890A1 (en) * 2020-04-16 2021-10-21 Adimabio Llc Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
CA3236051A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
ATE339960T1 (de) 1999-03-01 2006-10-15 Halogenetics Inc Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen
US6861513B2 (en) 2000-01-12 2005-03-01 Schering Corporation Everninomicin biosynthetic genes
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20050056280A1 (en) 2002-12-31 2005-03-17 Nektar Therapeutics Receptacle for an aerosolizable pharmaceutical formulation
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
MX2008001709A (es) 2005-08-01 2008-11-26 Nupotential Inc Produccion de celulas reprogramadas con potencial restablecido.
MX2010003261A (es) 2007-09-26 2010-08-18 Sinai School Medicine Analogos de azacitidina y usos de los mismos.
EP2050757A1 (en) * 2007-10-10 2009-04-22 Cilag AG Method of producing 2' -deoxy-5-azacytidine (Decitabine)
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
LT3782612T (lt) 2008-05-15 2023-12-27 Celgene Corporation Geriamosios citidino analogų kompozicijos ir jų naudojimo būdai
US9265785B2 (en) * 2008-12-22 2016-02-23 The Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
US9259469B2 (en) 2008-12-22 2016-02-16 The Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
JP6063628B2 (ja) 2009-02-10 2017-01-18 セルジーン インターナショナル サルル ５−アザシチジンを用いる、非小細胞肺癌の治療方法
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
WO2010118010A1 (en) 2009-04-06 2010-10-14 Eisai Inc. Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
WO2010118013A1 (en) 2009-04-06 2010-10-14 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
CN102485232A (zh) * 2010-12-06 2012-06-06 苏州科耐尔医药科技有限公司 一种含地西他滨的药物组合物
MX2013006020A (es) * 2011-01-31 2013-10-01 Celgene Corp Composicion farmaceutica de analogos de citidina y metodos para su uso.
US8426143B2 (en) * 2011-05-24 2013-04-23 Saladax Biomedical Inc. Gemcitabine immunoassay
US9476099B2 (en) 2012-08-10 2016-10-25 Trustees Of Dartmouth College Method for determining sensitivity to decitabine treatment
US20140100182A1 (en) 2012-10-05 2014-04-10 The Cleveland Clinic Foundation Nanogel-Mediated Drug Delivery
WO2014143051A1 (en) 2013-03-15 2014-09-18 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer

Also Published As

Publication number Publication date
US20220152075A1 (en) 2022-05-19
JP2018538370A (ja) 2018-12-27
JP7194021B2 (ja) 2022-12-21
JP2022184941A (ja) 2022-12-13
MX2021007569A (es) 2022-06-09
WO2017096357A1 (en) 2017-06-08
CA3007357A1 (en) 2017-06-08
US11779591B2 (en) 2023-10-10
CN109789155A (zh) 2019-05-21
US20240165142A1 (en) 2024-05-23
EP3383406A4 (en) 2019-08-21
EP3960182A1 (en) 2022-03-02
EP3383406B1 (en) 2021-10-20
MX2018006790A (es) 2019-05-02
US11376270B2 (en) 2022-07-05
CA3007357C (en) 2023-12-05
US20200246368A1 (en) 2020-08-06
EP3383406A1 (en) 2018-10-10
DK3383406T3 (da) 2022-01-10

Similar Documents

Publication Publication Date Title
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
BR112017014258A2 (pt) anticorpos anti-cd47 e usos dos mesmos
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
DK3294770T4 (da) Terapeutiske og diagnostiske fremgangsmåder til cancer
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
CL2016000408A1 (es) Composiciones farmaceuticas que contienen diastereomeros macrolidos, metodos para su sintesis y usos terapeuticos.
BR112018011324A2 (pt) ?composições contendo decitabina, 5azacitidina e tetra-hidrouridina e usos das mesmas?
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
CL2018000622A1 (es) Acetamida tienodiazepinas de triazol y sus usos relacionados.
CY1120459T1 (el) Αντισωματα των χημειοκινων παν-elr+ cxc
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
MX2015011779A (es) Nucleosidos biciclicos unidos en puente.
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
HK1248140A1 (zh) 用於治療癌症或免疫性疾病的細胞外基質組合物
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
EA201791845A1 (ru) Твердые формы менахинолов
BR112015005789A2 (pt) Formulações que compreende idebenona, n-acetil- s-farnesil-l-cisteína e ergotioneína e usos das mesmas
BR112018074299A2 (pt) composições farmacêuticas compreendendo eteplirsen

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]